Alison Birtle
About
Alison Birtle is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, Alison Birtle has authored 117 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 51 papers in Surgery and 35 papers in Oncology. Recurrent topics in Alison Birtle's work include Prostate Cancer Treatment and Research (58 papers), Bladder and Urothelial Cancer Treatments (41 papers) and Radiopharmaceutical Chemistry and Applications (24 papers). Alison Birtle is often cited by papers focused on Prostate Cancer Treatment and Research (58 papers), Bladder and Urothelial Cancer Treatments (41 papers) and Radiopharmaceutical Chemistry and Applications (24 papers). Alison Birtle collaborates with scholars based in United Kingdom, France and United States. Alison Birtle's co-authors include Robert Huddart, Emma Hall, Rebecca Lewis, Jenny Donovan, Robert J. Jones, Sangeetha Paramasivan, Matthew R. Sydes, Nicholas D. James, Amit Bahl and Simon Chowdhury and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
In The Last Decade
Alison Birtle
112 papers receiving 2.4k citations
Hit Papers
Peers
Alison Birtle
M. Roumiguié France
Tracy M. Downs United States
Christian Thomas Germany
Edouard J. Trabulsi United States
Rodney Davis United States
Behfar Ehdaie United States
Thomas L. Jang United States
Kenneth G. Nepple United States
Ricardo Rendon Canada
A. Akdaş Türkiye
Citations per year, relative to Alison Birtle Alison Birtle (= 1×)
peers
M. Roumiguié
Countries citing papers authored by Alison Birtle
Since
Specialization
Citations
This map shows the geographic impact of Alison Birtle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Birtle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Birtle more than expected).
Fields of papers citing papers by Alison Birtle
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alison Birtle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Birtle. The network helps show where Alison Birtle may publish in the future.
Co-authorship network of co-authors of Alison Birtle
This figure shows the co-authorship network connecting the top 25 collaborators of Alison Birtle. A scholar is included among the top collaborators of Alison Birtle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Birtle. Alison Birtle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bahl, Amit, Amarnath Challapalli, Prantik Das, et al.. (2025). Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study.. Journal of Clinical Oncology. 43(5_suppl). 89–89.
2.
Gontero, Paolo, Alison Birtle, Otakar Čapoun, et al.. (2024). European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update. European Urology. 86(6). 531–549.
3.
Birtle, Alison, Luigi Formisano, V. Descamps, Peter Weisenseel, & Antoni Vilaseca. (2024). Early Identification and Management of Patients with Rash on Apalutamide. Oncology and Therapy. 12(3). 609–620.
4.
Jones, Robert J., Simon J. Crabb, Mark Linch, et al.. (2024). Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. British Journal of Cancer. 130(6). 897–907.
5.
Rouprêt, Morgan, Thomas Seisen, Alison Birtle, et al.. (2023). European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. European Urology. 84(1). 49–64.
6.
Hussain, Syed A., J.F. Lester, Richard A. Jackson, et al.. (2022). Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. White Rose Research Online (University of Leeds, The University of Sheffield, University of York).
7.
Crabb, Simon J., Sarah Danson, James W.F. Catto, et al.. (2021). Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clinical Cancer Research. 27(7). 1882–1892.
8.
James, Nicholas D., Hannah Rush, Noel W. Clarke, et al.. (2020). 611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476). Annals of Oncology. 31. S509–S509.
9.
Jones, Robert J., Thomas Powles, Simon J. Crabb, et al.. (2020). ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials. 21(1). 344–344.
10.
Fischer‐Valuck, Benjamin W., Jeff M. Michalski, Joanna Harton, et al.. (2020). Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. Clinical Genitourinary Cancer. 19(1). 41–46.e1.
11.
Wilson, Caroline, Leila Rooshenas, Sangeetha Paramasivan, et al.. (2018). Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. Trials. 19(1). 50–50.
12.
James, Nicholas D., Johann S. de Bono, Melissa Spears, et al.. (2017). Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). Annals of Oncology. 28. v620–v620.
13.
Shamash, Jonathan, Shah‐Jalal Sarker, Robert Huddart, et al.. (2017). A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Annals of Oncology. 28(6). 1333–1338.
14.
Rooshenas, Leila, Daisy Elliott, Julia Wade, et al.. (2016). Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians’ Practices across Six Randomised Controlled Trials. PLoS Medicine. 13(10). e1002147–e1002147.
15.
Angelergues, Antoine, Alison Birtle, Orazio Caffo, et al.. (2016). Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study. Annals of Oncology. 27. vi252–vi252.
16.
Langenhuijsen, Johan F., et al.. (2015). Surgical Management of Adrenocortical Carcinoma: Impact of Laparoscopic Approach, Lymphadenectomy, and Surgical Volume on Outcomes—A Systematic Review and Meta-analysis of the Current Literature. European Urology Focus. 1(3). 241–250.
17.
Birtle, Alison, Rebecca Lewis, J F Chester, et al.. (2013). 81 Peri-operative chemotherapy or surveillance in upper tract urothelial cancer (POUT – CRUK/11/027) – a randomised controlled trial to define standard post-operative management. European Urology Supplements. 12(1). e81–e82.
18.
Tytherleigh, M G, et al.. (2006). Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. The Surgeon. 4(6). 378–383.
19.
Birtle, Alison, et al.. (2005). Tumour markers for managing men who present with metastatic prostate cancer and serum prostate‐specific antigen levels of <10 ng/mL. British Journal of Urology. 96(3). 303–307.
20.
Birtle, Alison, Jacqueline C. Newby, & S.J. Harland. (2004). Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. British Journal of Cancer. 91(8). 1472–1476.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by M. Roumiguié Breakdown of academic impact, for papers by Tracy M. Downs Breakdown of academic impact, for papers by Christian Thomas Breakdown of academic impact, for papers by Edouard J. Trabulsi Breakdown of academic impact, for papers by Rodney Davis Breakdown of academic impact, for papers by Behfar Ehdaie Breakdown of academic impact, for papers by Thomas L. Jang Breakdown of academic impact, for papers by Kenneth G. Nepple Breakdown of academic impact, for papers by Ricardo Rendon Breakdown of academic impact, for papers by A. Akdaş